Anti-microbial coating innovations to prevent healthcare-associated infection

Commentary: Worldwide, millions of patients are affected annually by healthcare-associated infection (HCAI), impacting up to 80,000 patients in European Hospitals on any given day.[1] This represents not only public health risk, but also an economic burden. Through its Cooperation in Science and Technology

Twenty-nine countries join forces to prevent healthcare associated infectious diseases

Over sixty universities, research institutes and companies from twenty-nine European countries will jointly study the impact of applying antimicrobial (nano-)coatings on decreasing the spread of infections. The beneficial aspects of these measures will be assessed in the context of potential

Applications for Short Term Scientific Missions are opened till March 25th

Purpose of a Short-Term Scientific Mission STSM facilitates Researchers from COST Countries participating in COST Action [CA 15114] to go to an institution, organisation or research centre in another participating COST Country to foster collaboration and to perform empirical research.

Welcome at the AMiCI website!

AMiCI is the acronym of AntiMicrobial Coating Innovations. It is a consortium which was initiated by researchers at the Zuyd University of Applied Sciences in the Netherlands in 2012. AMiCI brings together stakeholders from different countries and disciplines, including knowledge

Research Coordination and Capacity-building Objectives

The main objective of AMiCI action is to develop, structure, coordinate and maintain a long-term, flexible and open European network in the field of AMC in healthcare. The scientific field encompasses R&D of materials and coatings, testing, legal aspects and

Rising threats from AntiMicriobial Resistance

Many efforts to reduce AMR have been initiated, are ongoing and have been concluded. However many of these have been proven to be only partially sufficient. In order to succeed, a holistic approach is needed (Communication from the Commission to

AMiCI Action in Relation to Existing Efforts at European Level

Coordination of the best European research resources and capabilities will form the necessary critical mass and develop the most advanced scientific approaches to tackle AMR, reversing its increasing trend, and leading to the sustainable use of antibiotics and treatments for

The state-of-the-art in AMC

Novel antibiotic drugs are scarce and increasing resistance against antimicrobial drugs is established. Innovations that tackle rising and prominent threats in healthcare are demanded. Preventive innovations are needed to minimize microbial pressure in bacterial “hotspots”, like hospitals, nursing homes or